Skip to main content

Table 3 Statistically significant results of network meta-analysis for all time periods of drug administration

From: Comparative efficacy of serotonin (5-HT3) receptor antagonists in patients undergoing surgery: a systematic review and network meta-analysis

  All ages Children only
Treatment comparison No. of studies MA estimate: OR (95 % CI) * NMA estimate: OR (95 % CI) No. of studies MA estimate: OR (95 % CI) * NMA estimate: OR (95 % CI)
Vomiting 238 RCTs and 12,781 patients 46 RCTs and 1,830 patients
Ondansetron vs. placebo 146 0.35 (0.32–0.39) 0.36 (0.33–0.40) 34 0.30 (0.24–0.38) 0.30 (0.24–0.38)
Granisetron vs. placebo 27 0.24 (0.16–0.34) 0.26 (0.21–0.34) 4 0.21 (0.08–0.56) 0.23 (0.12–0.48)
Dolasetron vs. placebo 7 0.42 (0.21–0.83) 0.44 (0.30–0.63) 3 0.41 (0.23–0.75) 0.39 (0.19–0.78)
Tropisetron vs. placebo 15 0.32 (0.22–0.48) 0.32 (0.23–0.43) 3 0.18 (0.09–0.36) 0.18 (0.08–0.41)
Ondansetron + DEX vs. placebo 12 0.16 (0.09–0.27) 0.16 (0.12–0.23) 5 0.06 (0.03–0.17) 0.07 (0.03–0.15)
Palonosetron vs. placebo 4 0.53 (0.38–0.73) 0.38 (0.24–0.60) NA NA NA
Ramosetron vs. placebo 5 0.42 (0.26–0.68) 0.28 (0.18–0.43) NA NA NA
Ondansetron + DROP vs. placebo 2 0.15 (0.07–0.31) 0.14 (0.08–0.26) 1 0.13 (0.05–0.33) 0.11 (0.04–0.33)
Ondansetron + METO vs. placebo 2 0.16 (0.06–0.43) 0.15 (0.06–0.42) 2 0.16 (0.06–0.43) 0.18 (0.06–0.53)
Granisetron + DEX vs. placebo 5 0.16 (0.08–0.31) 0.15 (0.09–0.24) 2 0.08 (0.03–0.27) 0.09 (0.02–0.31)
Dolasetron + DEX vs. placebo 1 0.06 (0.01–0.30) 0.18 (0.06–0.49) NA NA NA
Dolasetron + DROP vs. placebo 1 0.16 (0.07–0.35) 0.19 (0.07–0.52) NA NA NA
Granisetron + DROP vs. placebo 2 0.30 (0.05–1.66) 0.31 (0.11–0.82) NA NA NA
Granisetron vs. ondansetron 12 0.52 (0.34–0.81) 0.73 (0.56–0.94) NA NA 0.78 (0.37–1.63)
Ondansetron + DEX vs. ondansetron 15 0.50 (0.33–0.75) 0.46 (0.33–0.63) 3 0.24 (0.12–0.47) 0.23 (0.11–0.49)
Ondansetron + DROP vs. ondansetron 5 0.43 (0.24–0.78) 0.39 (0.21–0.71) 1 0.31 (0.12–0.77) 0.37 (0.13–1.09)
Granisetron + DEX vs. ondansetron NA NA 0.41 (0.25–0.67) NA NA 0.28 (0.08–1.04)
Dolasetron vs. granisetron NA NA 1.66 (1.07–2.57) NA NA 1.65 (0.61–4.47)
Ondansetron + DEX vs. granisetron NA NA 0.63 (0.42–0.94) NA NA 0.30 (0.11–0.83)
Granisetron + DEX vs. granisetron 7 0.39 (0.20–0.77) 0.57 (0.35–0.92) 1 0.14 (0.02–1.23) 0.36 (0.09–1.50)
Ondansetron + DEX vs. dolasetron NA NA 0.38 (0.23–0.62) NA NA 0.18 (0.07–0.50)
Ondansetron + DROP vs. dolasetron NA NA 0.32 (0.16–0.65) NA NA 0.29 (0.08–1.04)
Granisetron + DEX vs. dolasetron NA NA 0.34 (0.19–0.63) NA NA 0.22 (0.05–0.95)
Ondansetron + DEX vs. tropisetron NA NA 0.52 (0.33–0.82) NA NA 0.40 (0.13–1.22)
Ondansetron + DROP vs. tropisetron NA NA 0.45 (0.23–0.88) NA NA 0.64 (0.16–2.48)
Granisetron + DEX vs. tropisetron NA NA 0.47 (0.26–0.84) NA NA 0.48 (0.10–2.25)
Palonosetron vs. ondansetron + DEX NA NA 2.32 (1.33–4.07) NA NA NA
Ramosetron vs. ondansetron + DEX NA NA 1.71 (1.01–2.90) NA NA NA
Palonosetron + DEX vs. ondansetron + DEX NA NA 8.68 (1.19–63.20) NA NA NA
Ondansetron + DROP vs. palonosetron NA NA 0.37 (0.17–0.78) NA NA NA
Granisetron + DEX vs. palonosetron NA NA 0.39 (0.20–0.75) NA NA NA
Palonosetron + DEX vs. ondansetron + DROP NA NA 10.13 (1.31–78.58) NA NA NA
Palonosetron + DEX vs. ondansetron + METO NA NA 9.38 (1.03–85.06) NA NA NA
Palonosetron + DEX vs. granisetron + DEX NA NA 9.60 (1.28–72.03) NA NA NA
Nausea 195 RCTs and 24,230 patients 11 RCTs and 1,326 patients
Ondansetron vs. placebo 121 0.46 (0.40–0.52) 0.46 (0.41–0.52) 10 0.44 (0.29–0.68) 0.45 (0.30–0.66)
Granisetron vs. placebo 21 0.35 (0.23–0.52) 0.35 (0.26–0.47) NA NA NA
Dolasetron vs. placebo 9 0.59 (0.48–0.73) 0.60 (0.43–0.86) 1 0.29 (0.11–0.73) 0.26 (0.09–0.74)
Tropisetron vs. placebo 15 0.51 (0.40–0.66) 0.48 (0.35–0.65) NA NA NA
Ondansetron + DEX vs. placebo 8 0.21 (0.14–0.34) 0.28 (0.19–0.41) 2 0.21 (0.08–0.57) 0.22 (0.08–0.61)
Palonosetron vs. placebo 3 0.48 (0.33–0.68) 0.30 (0.17–0.53) NA NA NA
Ramosetron vs. placebo 5 0.35 (0.18–0.68) 0.32 (0.22–0.47) NA NA NA
Ondansetron + DROP vs. placebo 2 0.31 (0.06–1.55) 0.26 (0.14–0.49) 1 0.07 (0.00–1.26) 0.07 (0.00–1.38)
Granisetron + DEX vs. placebo 4 0.21 (0.11–0.39) 0.20 (0.12–0.34) 1 0.09 (0.02–0.49) 0.10 (0.02–0.53)
Dolasetron + DEX vs. placebo 1 0.28 (0.05–1.53) 0.21 (0.07–0.61) NA NA NA
Dolasetron + DROP vs. placebo 1 0.17 (0.08–0.36) 0.19 (0.07–0.54) NA NA NA
Granisetron + DROP vs. placebo 2 0.22 (0.08–0.61) 0.21 (0.07–0.62) NA NA NA
Ondansetron + DEX vs. ondansetron 14 0.68 (0.48–0.96) 0.61 (0.42–0.89) 1 0.53 (0.11–2.60) 0.48 (0.16–1.43)
Granisetron + DEX vs. ondansetron NA NA 0.43 (0.25–0.73) NA NA 0.21 (0.04–1.23)
Dolasetron vs. granisetron NA NA 1.73 (1.10–2.72) NA NA NA
Granisetron + DEX vs. granisetron 6 0.59 (0.39–0.88) 0.56 (0.33–0.95) NA NA NA
Ondansetron + DEX vs. dolasetron NA NA 0.47 (0.28–0.78) NA NA 0.81 (0.19–3.50)
Palonosetron vs. dolasetron NA NA 0.50 (0.26–0.97) NA NA NA
Ramosetron vs. dolasetron NA NA 0.53 (0.31–0.88) NA NA NA
Ondansetron + DROP vs. dolasetron NA NA 0.44 (0.21–0.89) NA NA 0.28 (0.01–6.17)
Granisetron + DEX vs. dolasetron NA NA 0.33 (0.17–0.62) NA NA 0.36 (0.05–2.66)
Dolasetron + DEX vs. dolasetron 2 0.33 (0.15–0.72) 0.35 (0.13–0.97) NA NA NA
Dolasetron + DROP vs. dolasetron 1 0.35 (0.17–0.73) 0.32 (0.11–0.89) NA NA NA
Ondansetron + DEX vs. tropisetron NA NA 0.59 (0.36–0.95) NA NA NA
Granisetron + DEX vs. tropisetron NA NA 0.41 (0.22–0.76) NA NA NA
Postoperative nausea and vomiting 125 RCTs and 16,667 patients 14 RCTs and 2,394 patients
Ondansetron vs. placebo 89 0.30 (0.26–0.35) 0.31 (0.27–0.36) 11 0.33 (0.18–0.60) 0.34 (0.19–0.62)
Granisetron vs. placebo 16 0.23 (0.14–0.37) 0.23 (0.16–0.32) 2 0.54 (0.26–1.12) 0.32 (0.08–1.23)
Dolasetron vs. placebo 5 0.27 (0.14–0.52) 0.25 (0.14–0.43) NA NA NA
Tropisetron vs. placebo 8 0.39 (0.28–0.53) 0.36 (0.24–0.54) NA NA NA
Ondansetron + DEX vs. placebo 8 0.12 (0.07–0.20) 0.15 (0.10–0.22) 1 0.20 (0.06–0.66) 0.27 (0.04–1.61)
Palonosetron vs. placebo NA NA 0.11 (0.03–0.40) NA NA NA
Ramosetron vs. placebo 4 0.30 (0.15–0.59) 0.26 (0.16–0.41) NA NA NA
Ondansetron + DROP vs. placebo 2 0.13 (0.05–0.34) 0.11 (0.05–0.24) 1 0.12 (0.04–0.34) 0.12 (0.02–0.71)
Granisetron + DEX vs. placebo 4 0.06 (0.02–0.17) 0.09 (0.05–0.16) NA NA NA
Palonosetron + DEX vs. placebo NA NA 0.12 (0.02–0.64) NA NA NA
Dolasetron + DROP vs. placebo 1 0.17 (0.08–0.36) 0.12 (0.04–0.35) NA NA NA
Granisetron + DROP vs. placebo 2 0.17 (0.07–0.38) 0.16 (0.06–0.40) NA NA NA
Ondansetron + DEX vs. ondansetron 11 0.48 (0.33–0.72) 0.46 (0.31–0.69) 1 1.00 (0.36–2.75) 0.78 (0.13–4.65)
Ondansetron + DROP vs. ondansetron 3 0.39 (0.20–0.75) 0.35 (0.16–0.77) NA NA NA
Granisetron + DEX vs. ondansetron 1 0.22 (0.04–1.21) 0.30 (0.17–0.53) NA NA NA
Granisetron + DEX vs. granisetron 8 0.48 (0.29–0.77) 0.41 (0.24–0.69) NA NA NA
Granisetron + DEX vs. dolasetron NA NA 0.37 (0.17–0.82) NA NA NA
Ondansetron + DEX vs. tropisetron NA NA 0.41 (0.23–0.73) NA NA NA
Ondansetron + DROP vs. tropisetron NA NA 0.31 (0.13–0.75) NA NA NA
Granisetron + DEX vs. tropisetron NA NA 0.26 (0.13–0.52) NA NA NA
Granisetron + DEX vs. ramosetron NA NA 0.36 (0.18–0.75) NA NA NA
  1. * Meta-analysis was not conducted for treatment comparisons where only 1 trial was included. In that situation, the direct estimate was obtained from the single trial
  2. CI confidence interval, DEX dexamethasone, DROP droperidol (intravenous), MA meta-analysis, METO metoclopramide (intravenous), NA not applicable, NMA network meta-analysis, OR odds ratio
Back to article page

BMC Medicine

ISSN: 1741-7015

Contact us